Business Model Breakdown
How Alnylam Pharmaceuticals Inc Makes Money
ALNY
Market Cap
$39.9B
Annual Revenue
$3.4B
Profit Margin
13.5%
The Short Version
Alnylam Pharmaceuticals is a biotechnology company that discovers, develops, and commercializes RNA interference (RNAi) therapeutics, a novel class of medicines that silence specific genes to treat a wide range of diseases. The company generates revenue primarily through the sale of its approved products, which target rare genetic diseases like hereditary ATTR amyloidosis and acute hepatic porphyria, as well as more common conditions such as hypertension. Their business model involves extensive research and development, clinical trials, regulatory approvals, and then direct sales and marketing of their specialized medicines to healthcare providers and patients globally.
Where the Revenue Comes From
Total Net Product Revenues (~100% of reported Q1 2026 revenue)
TTR Franchise Product Revenue ($910 million in Q1 2026, ~87% of Q1 total revenue)
Who buys: Healthcare providers, hospitals, and patients primarily in rare disease and specialized treatment areas; future expansion to broader patient populations for hypertension.
Why It Works (Competitive Advantages)
- ✔Proprietary RNAi Therapeutics Platform and extensive IP moat
- ✔Multiple approved products with strong commercial momentum (e.g., TTR franchise)
- ✔Strategic AI collaboration (Inceptive Nucleics) enhancing drug discovery capabilities
- ✔Deep scientific expertise and established leadership in RNAi
Economic Moat: Narrow (Intangible Assets/IP (Patents on RNAi platform and specific drug molecules), Switching Costs (for patients on established therapies, and physicians accustomed to specific treatment protocols), Efficient Scale (in R&D and specialized manufacturing for RNAi therapies))
What Our Analysis Says
DVR Score as of June 11, 2026
Alnylam demonstrates significant 10x potential driven by a validated RNAi platform and exceptional commercial execution. Q1 2026 revenue surged 121% YoY to $1.036 billion, with TTR revenue growing over 150% YoY, signaling strong product adoption and market leadership. The strategic AI collaboration with Inceptive Nucleics (up to $2B) further strengthens its long-term pipeline. While 10x growth from a large-cap base requires flawless execution, particularly for Zilebesiran in hypertension, the current financial momentum, robust IP moat, and strong institutional backing provide a solid foundation. The primary risk lies in the highly competitive and regulated pharmaceutical landscape and the need for sustained pipeline success.